Cite
APA Citation
Ostadal, P., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V. A., Chua, T., Diaz, R., Goodman, S. G., Huo, Y., Jukema, J. W., Karpov, Y., Pordy, R., Scemama, M., Szarek, M., White, H. D., Schwartz, G. G., & , (2022). metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet, 10(5), 330–340. http://access.bl.uk/ark:/81055/vdc_100153783190.0x000018